KCNA3

Potassium voltage-gated channel subfamily A member 3 · P22001 · KCNA3 on Sugi Atlas →

40,275 patent compounds predicted against KCNA3, 24,074 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Bergapten (SCHEMBL50066)	0.66	10/20
Bezitramide (SCHEMBL25733)	0.54	10/20
Difenoxin (SCHEMBL123801)	0.78	9/20
Difenoxin (SCHEMBL149008)	0.76	9/20
Difenoximide (SCHEMBL121671)	0.72	9/20
Piritramide (SCHEMBL26151)	0.64	9/20
Bergaptol (SCHEMBL194016)	0.51	9/20
SCHEMBL28111	0.50	9/20
SCHEMBL29561	0.43	8/20
Fetoxylate (SCHEMBL124040)	0.74	6/20
Khellin (SCHEMBL9655)	0.69	6/20
Diphenoxylate (SCHEMBL42940)	1.00	5/20
Diphenoxylate (SCHEMBL42124)	0.98	5/20
SCHEMBL498762	0.59	5/20
Butoxylate (SCHEMBL241324)	0.82	4/20
Butoxylate (SCHEMBL239483)	0.74	4/20
Probenazol (SCHEMBL23516)	0.41	4/20
Phenoperidine (SCHEMBL80415)	0.83	3/20
Phenoperidine (SCHEMBL394330)	0.81	3/20
Anileridine (SCHEMBL26333)	0.74	3/20

Clinical trials — most relevant to KCNA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study	PHASE4	COMPLETED
Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atrial Fibrillation Undergoing Pulmonary Vein Antral Isolation	PHASE3	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo	PHASE2	COMPLETED
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy	PHASE1/PHASE2	RECRUITING
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet	PHASE1	NOT_YET_RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK	PHASE1	COMPLETED
Peripheral KV7 Activation for Pain Relief	EARLY_PHASE1	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Characteristics of Episodic Ataxia Syndrome	nan	COMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
A Positional Cloning Study on Schizophrenia	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
Involvement of SK3 Calcium Channel in Taxane Neuropathy	nan	COMPLETED
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNA3 binder may also engage these)

Protein	Name	Similarity
P15384	—	1.000	P15384 →
P19024	—	1.000	P19024 →
P16390	—	1.000	P16390 →
P17659	—	1.000	P17659 →
P50638	—	1.000	P50638 →
Q61762	—	0.998	Q61762 →
KCNA2	Potassium voltage-gated channel subfamily A member 2	0.998	landscape →
KCNA6	Potassium voltage-gated channel subfamily A member 6	0.998	landscape →
KCNA1	Potassium voltage-gated channel subfamily A member 1	0.997	landscape →
Q14B80	—	0.997	Q14B80 →
P22739	—	0.997	P22739 →
Q05037	—	0.997	Q05037 →
Q28527	—	0.997	Q28527 →
KCNA4	Potassium voltage-gated channel subfamily A member 4	0.996	landscape →
KCNA5	Potassium voltage-gated channel subfamily A member 5	0.996	landscape →
P63141	—	0.996	P63141 →
P63142	—	0.996	P63142 →
P15385	—	0.995	P15385 →
Q61423	—	0.995	Q61423 →
P25122	—	0.995	P25122 →
P16388	—	0.995	P16388 →
Q9I830	—	0.994	Q9I830 →
Q96PR1	—	0.994	Q96PR1 →
Q28293	—	0.993	Q28293 →
Q63734	—	0.993	Q63734 →
Q16322	—	0.991	Q16322 →
Q03721	—	0.991	Q03721 →
B2RQA1	—	0.991	B2RQA1 →
P22462	—	0.991	P22462 →
P79197	—	0.991	P79197 →